secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0000950170-25-057337
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Q1 net loss $45.6M ($0.41/sh); cash $852M; VK2735 Phase 3 expected 2Q25
------------------------------------------------------------------------------

- Net loss of $45.6M ($0.41 per share) vs $27.4M ($0.26) in Q1 2024; R&D expense rose to $41.4M.
- Cash, cash equivalents & short-term investments totaled $852M at March 31, 2025, down from $903M at Dec 31, 2024.
- Phase 3 trials for subcutaneous VK2735 in obesity expected to begin in 2Q25; Phase 2 VENTURE-Oral Dosing trial fully enrolled, data expected 2H25.
- Signed broad manufacturing agreement with CordenPharma for VK2735 API and fill/finish capacity; prepayments from 2025-2028 credited against future orders.
- Dual amylin/calcitonin receptor agonist (DACRA) program IND planned for 2H25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025057337/0000950170-25-057337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025057337/vktx-20250423.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-057337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer